We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Blog

Targeting Tau Pathology to Slow Alzheimer’s Disease Progression
Blog

To learn more about AC Immune's series of compounds designed to target tau aggregation, we recently spoke with Prof. Andrea Pfeifer, the company's Chief Executive Officer.

Read More

Size Matters: Diffusion Technique Sorts Out Pathological Proteins
Blog

Proteinopathies are diseases that feature misfolded proteins. In the brain, proteinopathies are rife, but research techniques are facing up to the challenge of studying these diseases. We talked to the University of Cambridge’s Tom Scheidt, whose research uses an innovative technique called diffusional sizing to better understand proteins.

Read More

Therapeutically Targeting DYRK1A in Alzheimer’s Disease
Blog

Alzheimer’s disease (AD) is a neurodegenerative condition. There are currently no FDA-approved disease‐modifying therapies for AD, despite it being the most common cause of dementia. We recently spoke with Samumed’s CEO Osman Kibar, to learn more about the company's efforts to therapeutically target "DYRK1A" in AD.

Read More

Simple Eye Measurement Helps Improve Outcomes for Brain Injury Patients
Blog

Pupillometry is an ingenious way of assessing brain health by measuring data from patients’ eyes. New technology has helped standardize pupillometry, and these measurements are now helping treat patients with life-threatening brain injuries. We spoke to Kathleen Pierson, Vice President, Global Sales and Marketing, at pupillometry leader NeurOptics, to find out more.

Read More

The Way Forward for Antibodies in Neuroscience
Blog

Antibodies are an essential part of everyday neuroscience research. But recently, high-profile criticism has cast doubt on their reliability and reproducibility. We caught up with Bio-Techne’s Raymond Chan and Katherine Bradley to find out how providers are hoping to improve antibodies and make them fit for a more reproducible future in neuroscience.

Read More

Entering the Antibody Lottery: Tips for Avoiding Dubious Sources
Blog

Having reliable antibodies can make or break your assay. However, sourcing the right antibody for the job can sometimes feel like you’re entering the lottery: there are so many on the market, and often they just don’t live up to what was promised. To learn more about antibody validation and its importance, we got in touch with Anthony Couvillon, PhD, Scientific Marketing Project Manager at Cell Signaling Technology.

Read More

Take a Good Book Around
Blog

Our recent social media poll on "book recommendations for scientists" provided an incredible response. We decided to collate this information and give you the perfect excuse to treat yourself to a new read. Enjoy!

Read More

The Vision for Multi-organ Human-on-a-Chip Models
Blog

The development of organ-on-a-chip models aims to reduce the (expensive) high drug failure rates that exist in clinical trials. A Florida biotech firm recently reported that their multi-organ “human-on-a-chip” system maintains cellular viability over 28 days in serum-free conditions, using a pumpless system. To learn more about the vision for multi-organ “human-on-a-chip” models, we caught up with James Hickman, Chief Science Officer of Hesperos Inc.

Read More

The Booming Business of Neurotoxin Therapy
Blog

Botulinum neurotoxins are widely used in both therapeutic and cosmetic applications, but Ipsen says that their new rBoNT-E toxin is a step up from compounds based on the much more widely used serotype A toxin. We spoke to Ipsen Senior Vice President Neurosciences R&D, Philippe Picaut, to find out more.

Read More

Harnessing AI in a Battle Against Aging
Blog

A recently announced collaboration between Juvenescence, Ltd., and NetraMark Corp. has yielded a new joint venture, NetraPharma, which aims to fight aging-related conditions. We spoke with NetraMark founder Dr. Joseph Geraci to find out more about how the process of targeting and treating neurodegenerative disorders will be radically changed by AI.

Read More